NAV

Bacillus calmette-guerin substrain connaught live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bacillus calmette-guerin substrain connaught live antigen
Accession Number
DB10804
Description

Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • BCG, Live, Connaught Strain

Pharmacology

Indication

Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Altretamine.
AmantadineThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amantadine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Unlock Additional Data
Bcg Vaccine (freeze-dried)Powder, for solutionIntradermalSanofi Pasteur Limited1961-12-312015-08-18Canada flag
ImmucystPowder, for suspensionIntravesicalSanofi Pasteur Limited1990-12-312018-01-31Canada flag
TheracysInjection, powder, lyophilized, for solution81 mg/3mLIntravesicalSanofi Pasteur Limited2011-07-222017-05-08US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
5H5854UBMZ
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910910
RxNav
76469
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCancer, Bladder1
3RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / COVID / COVID - 191
3RecruitingTreatmentCancer, Bladder2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionIntradermal
Powder, for suspensionIntravesical
Injection, powder, lyophilized, for solutionIntravesical81 mg/3mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:04 / Updated on January 25, 2021 22:38